tbuckley/cabot-search huggingface dataset:
Impact of neoadjuvant chemotherapy on breast reconstruction.
Authors: Y. Hu, C. M. Weeks, H. In, C. M. Dodgion, M. Golshan, Y. S. Chun, M. J. Hassett, X. Gu, S. R. Lipsitz, C. C. Greenberg
Journal: Journal of Clinical Oncology (2010)

6135 Background: Despite multiple studies confirming the efficacy of neoadjuvant chemotherapy and the safety of immediate reconstruction, little is known about the influence of chemotherapy timing on decisions about reconstruction. We hypothesize that patients who receive neoadjuvant chemotherapy are less likely to have immediate reconstruction, possibly due to chemotherapy-related complications. Methods: We identified 684 patients with stage I-III breast cancer who underwent chemotherapy and mastectomy at Dana-Farber/Brigham and Women's Cancer Center in 1997-2007. Using multivariate logistic regression, we compared rates of reconstruction for recipients of neoadjuvant chemotherapy (n = 180) to those of patients who underwent mastectomy prior to chemotherapy (n = 504). We then determined the rate of post-operative complications following neoadjuvant chemotherapy. Results: Recipients of neoadjuvant therapy were reconstructed at a rate of 42%, compared to 56% of patients receiving only adjuvant chemotherapy. Reconstruction was performed immediately in 23% vs. 44%, while 19% vs. 12% received delayed reconstruction. After controlling for age, receipt of radiotherapy, and stage, neoadjuvant recipients were less likely to have immediate reconstruction (OR 0.59, 95% CI 0.38, 0.91), and, if not immediately reconstructed, were not significantly more likely to undergo delayed reconstruction (OR 1.31, 95% CI 0.75, 2.29). There was no association between neoadjuvant chemotherapy-related complications and receipt of reconstruction. Surgical complications occurred in 36% of neoadjuvant recipients. Although this rate was higher in patients who received immediate reconstruction compared to those who did not, the difference was not significant on univariate (45% vs. 33%, p = 0.20) or multivariate analyses. Conclusions: Patients receiving neoadjuvant chemotherapy are less likely to have immediate reconstruction, and are no more likely to receive delayed reconstruction, than patients who undergo an operation before chemotherapy. While further study is needed to understand the etiology, this information should be incorporated into treatment decisions regarding timing of chemotherapy and surgery to optimize clinical outcome. No significant financial relationships to disclose.
Functional and clinical long-term outcome of Ewing sarcoma treatment*.
Authors: Andreas Ranft, Christiane Hoffmann, Corinna Winter, Ann-Christin Warby, Dieter Rosenbaum, Uta Dirksen, Herbert Juergens
Journal: Journal of Clinical Oncology (2015)

10529 Background: Since 1980 patients with Ewing sarcoma have been treated according to consecutive protocols (CESS) of the German Society of Pediatric Oncology and Hematology (GPOH). Rising survival rates have raised the question of the quality of long-term survivorship. Objective and subjective measurement tools are used to evaluate the actual health status and daily-life activity level as an indicator for restitution of function. Methods: Long-term outcome of 603 survivors of the CESS 81, CESS 86, EICESS 92, and EURO-E.W.I.N.G. 99 trials, run by the GPOH, diagnosed between 1980 and 2009, was assessed by the Toronto Extremity Salvage Score (TESS), Short-Form Health Survey (SF-36), and Brief Symptom Inventory (BSI) questionnaire scales, and by the StepWatch Activity Monitor (SAM) accelerometer device. Prospective data were correlated retrospectively with standardized primary trial data. A 1:2 non-random peer control group was selected to compare results with healthy individuals. Median age of former patients was 28.7 years, 56% were males. Median observation time was 12.9 years (range 3.7-31.2). Results: Former patients were less active than the control group, contributing to a mean step count difference of 1758 steps per day (10394 vs. 12152; p < .01), but have reached the recommended level for an active life-style ( > 10000). Negative prognostic factors were pelvic tumors (9265; p < .01) and primary metastatic disease (9322; p < .05). Correlations between self-reported scales and the step measurement were rather low (r < .30). The TESS score ( > 90), BSI somatization, anxiety and depression scales (raw values < 0.50), and the SF-36 (Physical/Mental Component Summary scores = 47.9/49.7) showed no major clinical or functional limitations. Around 15% of former patients rated their health status as less good or poor compared to 2% of the controls. Conclusions: The present study comprised a follow-up period of up to 30 years after the treatment of Ewing sarcoma. Former patients seemed to return to a normal lifestyle with minor limitations. The outcome is an encouraging signal to patients with this severe disease. *supported by BMBF/DLR 01ER0807
Plus Disease in Retinopathy of Prematurity
Authors: Jayashree Kalpathy-Cramer, J. Peter Campbell, Deniz Erdogmus, Peng Tian, Dharanish Kedarisetti, Chace Moleta, James D. Reynolds, Kelly Hutcheson, Michael J. Shapiro, Michael X. Repka, Philip Ferrone, Kimberly Drenser, Jason Horowitz, Kemal Sonmez, Ryan Swan, Susan Ostmo, Karyn E. Jonas, R.V. Paul Chan, Michael F. Chiang, Michael F. Chiang, Susan Ostmo, Kemal Sonmez, J. Peter Campbell, R.V. Paul Chan, Karyn Jonas, Jason Horowitz, Osode Coki, Cheryl-Ann Eccles, Leora Sarna, Audina Berrocal, Catherin Negron, Kimberly Denser, Kristi Cumming, Tammy Osentoski, Tammy Check, Mary Zajechowski, Thomas Lee, Evan Kruger, Kathryn McGovern, Charles Simmons, Raghu Murthy, Sharon Galvis, Jerome Rotter, Ida Chen, Xiaohui Li, Kent Taylor, Kaye Roll, Jayashree Kalpathy-Cramer, Deniz Erdogmus, Maria Ana Martinez-Castellanos, Samantha Salinas-Longoria, Rafael Romero, Andrea Arriola, Francisco Olguin-Manriquez, Miroslava Meraz-Gutierrez, Carlos M. Dulanto-Reinoso, Cristina Montero-Mendoza
Journal: Ophthalmology (2016)
Estimation of JAK2 V617F Prevalence by Detection of the Mutation in Saliva Samples From Online MPN and General Population Cohorts
Authors: Kimberly E. Barnholt, David A. Hinds, Amy K. Kiefer, Chuong B. Do, Nicholas Eriksson, Joanna L. Mountain, Uta Francke, Joyce A. Tung, Huong (Marie) Nguyen, Ross L. Levine, Ruben A. Mesa, Jason Gotlib, James L. Zehnder
Journal: Blood (2012)
Active-target T<sub>1</sub>-weighted MR Imaging of Tiny Hepatic Tumor <i>via</i> RGD Modified Ultra-small Fe<sub>3</sub>O<sub>4</sub> Nanoprobes
Authors: Zhengyang Jia, Lina Song, Fengchao Zang, Jiacheng Song, Wei Zhang, Changzhi Yan, Jun Xie, Zhanlong Ma, Ming Ma, Gaojun Teng, Ning Gu, Yu Zhang
Journal: Theranostics (2016)

Developing ultrasensitive contrast agents for the early detection of malignant tumors in liver is highly demanded.Constructing hepatic tumors specific targeting probes could provide more sensitive imaging information but still faces great challenges.Here we report a novel approach for the synthesis of ultra-small Fe3O4 nanoparticles conjugated with c(RGDyK) and their applications as active-target T1-weighted magnetic resonance imaging (MRI) contrast agent (T1-Fe3O4) for imaging tiny hepatic tumors in vivo.RGD-modified T1-Fe3O4 nanoprobes exhibited high r1 of 7.74 mM -1 s -1 and ultralow r2/r1 of 2.8 at 3 T, reflecting their excellent T1 contrast effect at clinically relevant magnetic field.High targeting specificity together with favorable biocompatibility and strong ability to resist against non-specific uptake were evaluated through in vitro studies.Owing to the outstanding properties of tumor angiogenesis targeting with little phagocytosis in liver parenchyma, hepatic tumor as small as 2.2 mm was successfully detected via the T1 contrast enhancement of RGD-modified T1-Fe3O4.It is emphasized that this is the first report on active-target T1 imaging of hepatic tumors, which could not only significantly improve diagnostic sensitivity, but also provide post therapeutic assessments for patients with liver cancer.
Phase Ib study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
Authors: Xing-Sheng Hu, Yuan-Kai Shi, Lin Wang, Lin Lin, Xiao-Hong Han, Zhi-Yun Meng, Gui-Fang Dou, Yan Sun
Journal: Journal of Clinical Oncology (2013)

e19075 Background: Chidamide (CS055) is a new benzamide type of histone deacetylase (HDAC) inhibitor with subtype selective activity against HDAC1, 2, 3 and 10. Synergistic effect of chidamide combined with paclitaxel and carboplatin (PC) have been demonstrated in various in vitro studies. Chidamide has shown well-tolerated and favorable PK profiles in patients (pts) with advanced solid tumors and lymphomas.This phase Ib study was designed to assess the safety and pharmacokinetics of chidamide plus PC in pts with advanced non-small cell lung cancer (NSCLC). Methods: Chemonaive pts with stage IIIb or IV NSCLC were treated with the escalating doses of chidamide (20, 25, and 30mg) plus PC. Chidamide was oral administered twice per week. Paclitaxel (175 mg/m 2 ) and carboplatin (AUC 5 mg·min/mL) were given both on day 1 every 3 weeks. Pts with response or stable disease after four cycles maintained single chidamide therapy until disease progression or unacceptable toxicity. Results: No DLT was observed in the 20 mg (n=3) and 25 mg (n=3) cohorts. 2 DLTs occurred in the 30 mg cohort (n=4), where 1 pt experienced grade 4 thrombocytopenia at the end of the first cycle, and the other developed grade 3 neutropenia and grade 2 thrombocytopenia resulting in the delay of the 2nd treatment cycle for &gt; 14 days. Therefore, chidamide in 25 mg was determined to be the MTD with this combination regimen. ≥ Grade 3 toxicities were thrombocytopenia (n=3) and neutropenia (n=1). 1 pt experienced grade 1 prolonged QTc. Co-administration had no significant effect on clearance of either chidamide or paclitaxel. 1 pt in the 20 mg cohort had confirmed partial response. Of 5 pts with brain metastases, 2 of them had complete disappearance of brain tumors after 4-cycle treatment. Conclusions: Chidamide plus PC was safe and well tolerated, with no apparent chidamide-paclitaxel pharmacokinetic interaction. Preliminary efficacy results suggest that chidamide combined with PC could provide benefit to NSCLC pts, with a potential interest of further observation of brain metastasis control in NSCLC with this regimen. Clinical trial information: ChiCTR-ONC-12002283.
Pitfalls in the Performance and Interpretation of Scintigraphic Imaging for Pleuroperitoneal Shunt
Authors: Matthew F. Covington, Gagandeep Choudhary, Ryan J. Avery, Phillip H. Kuo
Journal: Clinical Nuclear Medicine (2016)

Ascites can cause pleural effusions when the peritoneal fluid crosses the diaphragm through a pleuroperitoneal shunt in the setting of hepatic cirrhosis (hepatic hydrothorax) or malignant ascites. Scintigraphic imaging for pleuroperitoneal shunt requires intraperitoneal injection of Tc-SC or Tc-macroaggregated albumin followed by planar imaging of the chest and abdomen. Pleuroperitoneal shunt is confirmed by identifying radiotracer crossing the diaphragm from the peritoneal to pleural space. An atlas of pleuroperitoneal shunt imaging pitfalls is presented to facilitate optimal performance and interpretation of nuclear pleuroperitoneal shunt examinations. Examples include cases of nondiagnostic radiotracer injections, processing errors, and nontarget uptake.
Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging
Authors: Bruce J. Tromberg, Zheng Zhang, Anaïs Leproux, Thomas D. O'Sullivan, Albert E. Cerussi, Philip M. Carpenter, Rita S. Mehta, Darren Roblyer, Wei Yang, Keith D. Paulsen, Brian W. Pogue, Shudong Jiang, Peter A. Kaufman, Arjun G. Yodh, So Hyun Chung, Mitchell Schnall, Bradley S. Snyder, Nola Hylton, David A. Boas, Stefan A. Carp, Steven J. Isakoff, David Mankoff
Journal: Cancer Research (2016)

Abstract The prospective multicenter ACRIN 6691 trial was designed to evaluate whether changes from baseline to mid-therapy in a diffuse optical spectroscopic imaging (DOSI)–derived imaging endpoint, the tissue optical index (TOI), predict pathologic complete response (pCR) in women undergoing breast cancer neoadjuvant chemotherapy (NAC). DOSI instruments were constructed at the University of California, Irvine (Irvine, CA), and delivered to six institutions where 60 subjects with newly diagnosed breast tumors (at least 2 cm in the longest dimension) were enrolled over a 2-year period. Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, and TOI (ctHHb × ctH2O/lipid) were acquired on both breasts up to four times during NAC treatment: baseline, 1-week, mid-point, and completion. Of the 34 subjects (mean age 48.4 ± 10.7 years) with complete, evaluable data from both normal and tumor-containing breast, 10 (29%) achieved pCR as determined by central pathology review. The percent change in tumor-to-normal TOI ratio (%TOITN) from baseline to mid-therapy ranged from −82% to 321%, with a median of −36%. Using pCR as the reference standard and ROC curve methodology, %TOITN AUC was 0.60 (95% CI, 0.39–0.81). In the cohort of 17 patients with baseline tumor oxygen saturation (%StO2) greater than the 77% population median, %TOITN AUC improved to 0.83 (95% CI, 0.63–1.00). We conclude that the combination of baseline functional properties and dynamic optical response shows promise for clinical outcome prediction. Cancer Res; 76(20); 5933–44. ©2016 AACR.
Impact of Immunoglobulin Heavy Chain (IGH) Translocations In Chronic Lymphocytic Leukemia (CLL): Negative Effect on Patients with Isolated Deletion 13q Abnormality
Authors: Alina S. Gerrie, Tanya L. Gillan, Helene Bruyere, Mary Joyce Chan, Chinmay B. Dalal, Cynthia L. Toze
Journal: Blood (2010)
Ulcers of the Ventral Aspect of Fingers
Authors: Sungat K. Grewal, Chris T. Derk, Misha Rosenbach
Journal: JAMA Dermatology (2016)

A 42-year-old African American man presented with a 7-month history of fatigue, exertional dyspnea, arthralgias, hand swelling, tender ulcerations, hair loss, and a 50-pound weight loss; he presented with ulcers on his dorsal metacarpophalangeal joints. What is your diagnosis?
The Relevance of Stem Cell Load at Diagnosis for the Development of Relapse in Pediatric Acute Myeloid Leukemia
Authors: Dirkje W. Hanekamp, Barbara Denys, Gertjan J.L. Kaspers, Jeroen G. te Marvelde, Gerrit Jan Schuurhuis, Valerie De Haas, Barbara De Moerloose, Eveline S. de Bont, Anja de Jong, Jan Philippé, Jacqueline Cloos, Vincent H.J. van der Velden
Journal: Blood (2015)
P17 Anticoagulation for liver fibrosis: a pilot study in hepatitis C infected patients
Authors: A Dhar, Q Anstee, J Cobbold, J Stove, A Martinelli, S Taylor-Robinson, M Thursz
Journal: Gut (2010)

Introduction  Therapy directed towards the underlying cause of liver disease is not always successful, and anti-fibrotics are urgently required to slow disease progression in these patients. Recent evidence demonstrates a role for the coagulation cascade in promoting liver fibrosis. It is accepted that thrombin can activate hepatic stellate cells via PAR1 cleavage and we have previously shown that the prothrombotic Factor V Leiden mutation is associated with accelerated fibrosis in chronic HCV infection. Further, in animal studies, we have shown that warfarin anticoagulation ameliorates hepatic fibrosis. There is now an urgent need to evaluate the effect of anticoagulation on hepatic fibrosis in human studies.  Aim  To evaluate the safety and impact of warfarin anticoagulation on the progression of liver fibrosis using non-invasive tests in HCV patients: a pilot study.  Method  HCV patients (n=10, mean age 49.5 years, range 42–62 years, 6=M, 4=F) with moderate fibrosis (Ishak stage 3–4), who had previously failed anti-viral therapy were enrolled. Routine blood tests, liver stiffness measurements and serum markers of fibrosis (ELF testing), were performed at 0, 8 and 16 weeks. A subset of patients (n=5) had hepatic transit times performed at each time point. Patients were given no anticoagulation between 0 and 8 weeks (observation period) and anticoagulated with warfarin to maintain an INR of 2–3 between 8 and 16 weeks (treatment period). Wilcoxon signed ranks test used to compare paired data.  Results  Warfarin anticoagulation significantly reduced median liver stiffness values (8 vs 16 weeks: 9.60 vs 6.90 kPa, p=0.012; 0 vs 16 weeks 7.70 vs 6.90 kPa, p=0.043). There was no significant difference in liver stiffness values between the start and end of the observation period. A non significant trend towards prolongation was seen in mean hepatic transit times following anticoagulation (11.0 vs 12.1 s; p=0.23). There were no significant differences between ELF test scores, serum ALT values and APRI scores following anticoagulation. No serious adverse events were reported during the anticoagulation period. One patient had a minor adverse event, requiring temporary cessation of warfarin treatment, and was excluded from the analysis.  Conclusion  A short period of warfarin anticoagulation demonstrated a significant improvement in liver stiffness measurements in HCV patients with pre-existing moderate fibrosis, with no major adverse events. These results suggest that warfarin anticoagulation may have a beneficial effect on liver fibrosis in HCV patients. Larger human studies are required to further evaluate its anti-fibrotic potential.
Functional Consequences Of RPS29 Germline Mutations In Diamond-Blackfan Anemia
Authors: Lisa Mirabello, Elizabeth R Macari, Lea Jessop, Timothy Myers, Neelam Giri, Alison M. Taylor, Katherine E. McGrath, Jessica M. Humphries, Bari J Ballew, Meredith Yeager, Joseph F Boland, Ji He, Belynda D Hicks, Laurie Burdett, Blanche P Alter, Leonard I. Zon, Sharon A Savage
Journal: Blood (2013)
Marriage Equality Act and Changes to Health Insurance Coverage—Reply
Authors: Gilbert Gonzales
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Poor quality data from diet studies may dilute better quality evidence
Authors: George D Henderson
Journal: BMJ (2016)

The hypothesis behind Farvid and colleagues’ study,1 that cancer risk is modified early in life by micronutrients and other factors, is plausible. However, the data collection method—nostalgic re-creation of adults’ childhood diet—invites respondents to invent data.

I vaguely remember vegetables I ate in adolescence, in meals my mother cooked, but I can’t accurately recall fruit consumption. Yet the exclusion criteria …
Diagnostic testing in primary ciliary dyskinesia
Authors: Jane S. Lucas, Borislav D. Dimitrov, Laura Behan, Claudia E. Kuehni
Journal: European Respiratory Journal (2016)

We thank very much I. Amirav and P.M. Boussuyt for their interest in our manuscripts [1, 2]. We agree that our two studies have some limitations, caused by the lack of a "gold standard" test for diagnosing primary ciliary dyskinesia (PCD), but we strongly disagree with their claim that we "did not notify the readers of these design deficiencies". Instead, we had taken great care to highlight these uncertainties and risks of bias. Keeping up the momentum to develop an evidence base for the diagnosis of PCD <http://ow.ly/o6zq300uhcw>
Co-Stimulatory Blockade With CTLA4-Ig Permits Transplantation Of Human Hematopoietic Stem Cells and HLA Incompatible T Cells In NOD/SCID γ Null (NSG) Mouse Model
Authors: Annie L. Oh, Dolores Mahmud, Benedetta Nicolini, Nadim Mahmud, Elisa Bonetti, Pritesh R. Patel, Damiano Rondelli
Journal: Blood (2013)
First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel.
Authors: Stephane Oudard, Lisa Sengelov, Paul N. Mainwaring, Antoine Thiery- Vuillemin, Christine Theodore, Evgeny Kulikov, Jeffrey Yachnin, Ivo Kocak, Vesa V Kataja, Marjaana Luukkaa, Aleander Nosov, Marie Hjelm-Eriksson, Jeffrey Bubis, Liji Shen, Marie-Laure Risse, A. Oliver Sartor
Journal: Journal of Clinical Oncology (2012)

TPS4696^ Background: Docetaxel (D) in combination with prednisone (P) as first-line (1L) chemotherapy in patients (pts) with mCRPC is the current standard of care. However, treatment is not curative and D-resistant disease typically develops. Cabazitaxel (Cbz) is a novel taxane active in D-sensitive and -resistant tumor models. Clinical activity of Cbz plus P (CbzP) was demonstrated in the Phase III TROPIC study in mCRPC pts previously treated with a D-containing regimen; CbzP showed a significant overall survival (OS) benefit vs mitoxantrone plus prednisone (median OS 15.1 vs 12.7 months; HR 0.70; P &lt; 0.0001). Therefore, it is of interest to determine if CbzP provides an OS advantage vs DP in 1L mCRPC pts. Methods: The phase III FIRSTANA study (NCT01308567) is a randomized, open-label, multinational trial in 1L mCRPC pts, designed to compare the efficacy of Cbz 25 mg/m² IV Q3W (Arm A) and Cbz 20 mg/m² IV Q3W (Arm B) vs D 75 mg/m 2 IV Q3W (Arm C). P 10 mg PO QD is to be given concomitantly. Pts are stratified by ECOG PS (0–1 vs 2), measurable disease (yes/no) and region (depending on availability of Cbz as 2L). Pts with ECOG PS ≤ 2, histologically/cytologically confirmed metastatic prostate adenocarcinoma, with no prior chemotherapy and with disease progression following medical or surgical castration are eligible. The primary endpoint is OS. Secondary endpoints include progression-free survival (PFS) (PCWG2 criteria), radiologic PFS, tumor response in measurable disease (RECIST 1.1), PSA response and PSA PFS, pain response and pain PFS, time to occurrence of any skeletal-related events, safety profile and health-related quality of life. Cbz pharmacokinetics and pharmacogenomics will be assessed in pt subgroups. Pts will be treated until progression, unacceptable toxicity or pt request. Planned enrollment is 1,170 pts; study size was calculated to achieve 90% power for OS. Study start was in May 2011; at January 2012, 219 pts were enrolled. The first DMC meeting recommended continuing the study without change.